Tuesday 20 October 2026 Export INCY’s income statement to Excel — free account

Incyte Corporation

Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 39.7%, free cash flow grew 1,829.5% and total debt fell 10.5%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.

115.09 1.84 +1.62%

Follow INCY

Alert me

Market cap: $23.0B
P/E: 13.9×
Fwd P/E: 58.4×
Dividend yield: —
F-score: 9/9
Altman Z: 8.57
Beneish M: −2.43
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Incyte Corporation (INCY) P/E ratio

Alert me on P/E ratio

As of 19 October 2026, Incyte Corporation (INCY) trades at a P/E ratio of 13.9×. Over the past ten years it has ranged from 0.0× (March 2021) to 5,423× (December 2015); the current reading is higher than 32% of that period. That is above the Biotechnology industry median of 8.4× and below the Healthcare sector median of 22.9×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/INCY/pe-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Incyte Corporation P/E ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/INCY/metrics/pe-ratio">Incyte Corporation (INCY) P/E ratio — stockrow.com</a></p>

Period	P/E ratio	Change
FY2025	15.0×	(93.28%)
FY2024	223×	808.93%
FY2023	24.5×	(52.55%)
FY2022	51.7×	201.91%
FY2021	17.1×	—
FY2020	0.0×	—
FY2019	42.0×	(65.67%)
FY2018	122×	—
FY2017	0.0×	—
FY2016	183×	(96.63%)

Period	P/E ratio	Change
Jun 2026	13.9×	8.15%
Mar 2026	12.9×	(13.85%)
Dec 2025	15.0×	7.99%
Sep 2025	13.9×	(8.43%)
42 more quarters	Free account

Against its own ten years

Low 0.0× High 5,423×

Ten-year median 19.4×

Current reading's percentile 3

Company	P/E ratio
BNTX BioNTech SE Sponsored ADR compare	n/m
INSM Insmed, Inc. compare	n/m
ROIV Roivant Sciences Ltd. compare	n/m
INCY Incyte Corporation	13.9×
ASND Ascendis Pharma A/S compare	16.6×
EXEL Exelixis, Inc. compare	19.0×
GMAB Genmab A/S Sponsored ADR compare	30.3×
ALNY Alnylam Pharmaceuticals, Inc. compare	39.8×
RPRX Royalty Pharma PLC compare	41.7×
Biotechnology industry median	8.4×
Healthcare sector median	22.9×
Market median	18.0×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

Incyte Corporation (INCY) P/E ratio

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on INCY

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on INCY

Stockrow Weekly